We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

172 hedge funds and large institutions have $813M invested in Ariad Pharmaceuticals Inc in 2015 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 55 increasing their positions, 56 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more call options, than puts

Call options by funds: $14.1M | Put options by funds: $10.1M

1% more capital invested

Capital invested by funds: $802M → $813M (+$10.9M)

2% less repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 56

8% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 26

2% less funds holding

Funds holding: 175172 (-3)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
172
Holders Change
-3
Holders Change %
-1.71%
% of All Funds
4.5%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.1%
New
24
Increased
55
Reduced
56
Closed
26
Calls
$14.1M
Puts
$10.1M
Net Calls
+$4.05M
Net Calls Change
+$2.22M

ARIA Hedge Fund Activity: Q4 2015 in Review

172 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2015, worth a combined $813M — up 1.4% from $802M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of ARIA and 24 opened new positions — a net loss of 2 holders — while 56 trimmed existing stakes and 55 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $6.68M. The largest seller was Putnam Investments, cutting an estimated $32M.

  • 172 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2015, down from 175 in Q3 2015.
  • Funds reported $813M of Ariad Pharmaceuticals Inc stock for Q4 2015, up 1.4% quarter-over-quarter.
  • 24 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2015 and 26 closed out, a net change of -2 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2015 was D.E. Shaw & Co, an estimated $6.68M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2015 was Putnam Investments, an estimated $32M sold.

Based on aggregated 13F filings for Q4 2015.